Tisochrysis Lutea Extract.

This microalga is a DHA-rich oil and long-chain polyunsaturated fatty acids oxidise readily once extracted. Tocopherol is the standard chain-breaking antioxidant added to keep the fatty acid intact in the capsule and after intake.

The oil from this alga is valued for its docosahexaenoic acid content, so it contributes to the same DHA intake as a declared DHA dose. Count the two together rather than as independent actives.

This alga is rich in DHA but carries little eicosapentaenoic acid, and retroconversion of DHA to EPA in humans is limited. An EPA source alongside it covers the part of the omega-3 profile the alga does not supply.

Astaxanthin spans the lipid bilayer and quenches radicals in the same membrane compartment where DHA is most vulnerable to peroxidation. It is a long-standing companion in algal and marine oil formulations.

Generous long-chain omega-3 intake shifts platelet eicosanoid balance and modestly lengthens normal clotting, and nattokinase acts on fibrin from another direction. The two effects add, which matters for anyone already using something that thins the blood.

Ginkgolides antagonise platelet-activating factor while long-chain omega-3s reduce thromboxane-driven platelet aggregation. Both nudge normal clotting in the same direction, so the combination should be accounted for.

Microalgal oil is dense in docosahexaenoic acid, a fatty acid with six double bonds and therefore a high susceptibility to peroxidation. Alpha-tocopherol sits in the membrane or the oil phase and stops the chain, but it is consumed doing so. Ascorbate in the aqueous phase reduces the resulting tocopheroxyl radical back to tocopherol, which is why the two are described as a redox couple rather than two separate antioxidants. This is chemistry, not a measured outcome for this algae.

Long-chain polyunsaturated fatty acids delivered by algal oil are incorporated into membrane phospholipids, where peroxidation products have to be reduced enzymatically. Glutathione peroxidase 4 does that work and it is a selenoprotein, so selenium status sets the ceiling on that capacity. The relationship is a cofactor relationship, established biochemistry rather than a trial result in people taking this extract.

After absorption, a large share of circulating docosahexaenoic acid travels esterified into phosphatidylcholine species assembled in the liver, and the lysophosphatidylcholine form is the species carried across the blood brain barrier by the MFSD2A transporter. Choline supplies the headgroup for both. That makes choline availability part of how dietary docosahexaenoic acid is distributed, an established pathway rather than a demonstrated additive effect of the two supplements together.

Algal oil is a long-chain lipid, so its absorption depends on emulsification and micellar solubilisation in the small intestine. Where bile delivery is limited, supplemental bile acids are used in practice to restore micelle formation. The pharmacology of that step is settled; how much difference it makes for this particular extract has not been measured.

Docosahexaenoic acid presented as a triacylglycerol has to be cleaved at the sn-1 and sn-3 positions before uptake. Lipase performs that step, so supplemental lipase is a formulation and digestion consideration for any oil-based omega-3, algal or marine-animal. This is mechanism, not an effect size for the extract.

Whole-cell algal preparations keep some of their lipid behind a cell wall and inside polar lipid membranes rather than as free oil. Enzyme blends are used in practice to help release that fraction. The reasoning follows from lipid digestion chemistry; no trial in the candidate set tested the pairing.

Phosphatidylcholine lowers interfacial tension and helps disperse an oil into fine droplets, which increases the surface available to lipase. It also provides the same phospholipid class in which docosahexaenoic acid is normally carried. Formulators use it for both reasons; the claim here is about dispersion chemistry, not about a bigger clinical effect.

Spray-dried and emulsified algal oil products routinely carry lecithin as the emulsifier that keeps the oil phase dispersed and helps protect droplets during drying. That is a manufacturing role, described here so a reader knows why it appears on a label beside an algal oil. It is not a claim that lecithin adds a physiological benefit.

Blending a medium-chain oil into a long-chain omega-3 concentrate is common because it keeps the product fluid and provides a lipid load that stimulates bile and pancreatic secretion at the meal. The general principle that fat co-ingestion raises long-chain fatty acid absorption is well described. The specific gain from this blend with this extract has not been quantified in the candidate literature.

Coenzyme Q10 in its reduced form scavenges lipid radicals inside the same membrane and lipoprotein compartments where docosahexaenoic acid resides, and it can reduce tocopheroxyl radicals back to tocopherol. Products pairing an omega-3 with ubiquinol lean on that shared compartment. The evidence is mechanistic and in vitro in character, not a clinical demonstration for this algae.

Lutein needs dietary fat for micellar incorporation, and an algal oil supplies that fat in the same capsule. Retinal membranes are separately known to be rich in docosahexaenoic acid while the macular pigment is carotenoid based, so the two occupy different chemical roles in the same tissue. That is a rationale for co-formulation, not a measured combined outcome.

Zeaxanthin is absorbed poorly from a low-fat matrix and better when taken with an oil. Algal oil serves as that oil. The absorption principle is well established for carotenoids in general; nothing in the candidate set tested this pair.

Ferrous iron decomposes lipid hydroperoxides into alkoxyl and peroxyl radicals, which propagates a chain reaction through polyunsaturated acyl chains. That is why iron salts and unprotected polyunsaturated oils are kept apart in a formulation and why antioxidant systems are specified alongside both. This is a formulation and chemistry caution, not a statement about anyone's health.

One 2026 report on Tisochrysis lutea F&M-M36 describes modulation of gut microbiota and intestinal cholesterol handling, which places the algal matrix in the same compartment where live cultures act. Microbial composition is a marker, and the report is preclinical, so this is a plausible interaction rather than a demonstrated combined benefit. Anyone stacking the two should regard the pairing as untested in people.